REGULAR CONTENT
Final ID
555
Type
Original Scientific Research-Poster Only
Authors
M Haddad1, B Simmons1, I McPhail1, M Kalra1, M Neisen1, S Misra1, A Stockland1, J Andrews1, M McKusick1, H Bjarnason1
Institutions
1Mayo Clinic, Rochester, MN
Purpose
To identify whether symptom relief and stent patency vary with the use of covered or uncovered stents for the treatment of benign SVC syndrome.
Materials & Methods
We retrospectively identified all patients with benign SVC syndrome treated with stent placement between January 2003 and December 2015. Only cases with both clinical and imaging follow-up were included. Clinical and treatment outcomes, complications, and the percent stenosis of each stent were evaluated.
Results
Forty-seven patients were identified. 31(66%) cases were due to a chronic line/pacemaker, 14(30%) were due to fibrosing mediastinitis, and 1(2%) each were due to chronic thrombosis and an unknown reason. 17 (36%) had placement of a covered stent and 30(64%) had an uncovered stent. Technical success was achieved in all cases. There was a significant difference (p<0.05) in the number of patients who reported a return of symptoms between the covered (5/17 or 29.4%) and uncovered (18/30 or 60%) groups. There was also a significant difference (p<0.05) in the mean percent stenosis between the covered (20.2% (range: 1.7-54.2) +/- 20.3) and uncovered (59.9% (range: 13.2-100) +/- 32.2) groups. No significant difference was found in the time (days) between the date of procedure and date of return of symptoms (covered: 426.6 (range: 28-1554) +/- 633.9 and uncovered 778.1 (range: 23-3851) +/- 1066.8). None of the patients in the covered group went on to require surgical intervention while 2 (6.7%) in the uncovered group went on to surgical intervention. Return of symptoms was more common with an etiology of fibrosing mediastinitis (10/14 or 71.4%) than the line group (12/31 or 38.7%). One major complication (Clavien-Dindo grade 3 or greater) occurred that consisted of a pericardial hemorrhagic effusion after angioplasty that required covered stent placement. There were no procedure related deaths.
Conclusions
Both covered and uncovered stents are a safe and effective for treating benign SVC syndrome. Covered stents, however, are more effective at providing symptom relief and maintaining stent patency.
Final ID
555
Type
Original Scientific Research-Poster Only
Authors
M Haddad1, B Simmons1, I McPhail1, M Kalra1, M Neisen1, S Misra1, A Stockland1, J Andrews1, M McKusick1, H Bjarnason1
Institutions
1Mayo Clinic, Rochester, MN
Purpose
To identify whether symptom relief and stent patency vary with the use of covered or uncovered stents for the treatment of benign SVC syndrome.
Materials & Methods
We retrospectively identified all patients with benign SVC syndrome treated with stent placement between January 2003 and December 2015. Only cases with both clinical and imaging follow-up were included. Clinical and treatment outcomes, complications, and the percent stenosis of each stent were evaluated.
Results
Forty-seven patients were identified. 31(66%) cases were due to a chronic line/pacemaker, 14(30%) were due to fibrosing mediastinitis, and 1(2%) each were due to chronic thrombosis and an unknown reason. 17 (36%) had placement of a covered stent and 30(64%) had an uncovered stent. Technical success was achieved in all cases. There was a significant difference (p<0.05) in the number of patients who reported a return of symptoms between the covered (5/17 or 29.4%) and uncovered (18/30 or 60%) groups. There was also a significant difference (p<0.05) in the mean percent stenosis between the covered (20.2% (range: 1.7-54.2) +/- 20.3) and uncovered (59.9% (range: 13.2-100) +/- 32.2) groups. No significant difference was found in the time (days) between the date of procedure and date of return of symptoms (covered: 426.6 (range: 28-1554) +/- 633.9 and uncovered 778.1 (range: 23-3851) +/- 1066.8). None of the patients in the covered group went on to require surgical intervention while 2 (6.7%) in the uncovered group went on to surgical intervention. Return of symptoms was more common with an etiology of fibrosing mediastinitis (10/14 or 71.4%) than the line group (12/31 or 38.7%). One major complication (Clavien-Dindo grade 3 or greater) occurred that consisted of a pericardial hemorrhagic effusion after angioplasty that required covered stent placement. There were no procedure related deaths.
Conclusions
Both covered and uncovered stents are a safe and effective for treating benign SVC syndrome. Covered stents, however, are more effective at providing symptom relief and maintaining stent patency.